2008
IL-17 contributes to CD4-mediated graft-versus-host disease
Kappel L, Goldberg G, King C, Suh D, Smith O, Ligh C, Holland A, Grubin J, Mark N, Liu C, Iwakura Y, Heller G, van den Brink M. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2008, 113: 945-952. PMID: 18931341, PMCID: PMC2630280, DOI: 10.1182/blood-2008-08-172155.Peer-Reviewed Original ResearchConceptsRecipients of ILT cellsGVHD mortalityHost diseaseIL-17Proinflammatory cytokinesAllogeneic bone marrow transplantAllogeneic BMT modelIL-17 contributesDonor T cellsBone marrow transplantWhole T cellsT-cell recipientsAcute graftGVHD developmentGVT activityAllograft rejectionTh17 cellsIL-17FIL-22Interleukin-17Marrow transplantAutoimmune diseasesTh1 cellsLymphoid organs
2004
IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.
Hildebrandt G, Olkiewicz K, Choi S, Corrion L, Liu C, McKenzie A, Cooke K. IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?. Blood 2004, 104: 3070. DOI: 10.1182/blood.v104.11.3070.3070.Peer-Reviewed Original ResearchBALB/c ILStem cell transplantationDonor T cellsIL-13T cellsC ILSyngeneic controlsTNFa levelsAllo-SCTHost diseaseTh2 cytokinesDonor cellsAcute Graft Versus Host DiseaseGraft Versus Host DiseaseAllogeneic stem cell transplantationTh1-type cytokine responseAltered cytokine milieuDay 100 survivalRecipients of ILTypical Th2 cytokineSeverity of GVHDVersus Host DiseaseIL-13 levelsIL-5 levelsPathogenesis of GVHD